ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Kalytera Therapeutics Inc

Kalytera Therapeutics Inc (KLY)

0,045
0,00
(0,00%)
Fermé 25 Janvier 10:00PM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
0,045
Prix Achat
0,04
Prix Vente
0,045
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,045 Plage de 52 semaines 0,045
Clôture Veille
0,045
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

KLY Dernières nouvelles

Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce it has...

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Company’s...

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it will...

Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

SAN FRANCISCO, CA and TORONTO, ON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has...

Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

SAN FRANCISCO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that the...

Claritas Provides Update Regarding Phase 1 Clinical Study

SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today provided an update regarding...

Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQB

SAN FRANCISCO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") today announced the engagement of B...

Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC

SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") is pleased to announce that it has closed the...

Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS

SAN FRANCISCO and TORONTO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") today announced that it has entered...

Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107

SAN FRANCISCO and TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTD) (the "Company" or "Claritas") is pleased to announce that, subject...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1000.0450.0450.04500CS
4000.0450.0450.04500CS
12000.0450.0450.04500CS
26000.0450.0450.04500CS
52000.0450.0450.04500CS
156000.0450.0450.04500CS
260000.0450.110.013327170.04535964CS

KLY - Frequently Asked Questions (FAQ)

What is the current Kalytera Therapeutics share price?
The current share price of Kalytera Therapeutics is $ 0,045
What is the 1 year trading range for Kalytera Therapeutics share price?
Kalytera Therapeutics has traded in the range of $ 0,045 to $ 0,045 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
ADEAdex Mining Inc
$ 0,01
(100,00%)
1 000
DEALPlaygon Games Inc
$ 0,02
(100,00%)
1,75M
TVC.HThree Valley Copper Corp
$ 0,01
(100,00%)
15,6k
GBUGabriel Resources Ltd
$ 0,01
(100,00%)
167k
MACThemac Resources Group Ltd
$ 0,08
(60,00%)
3k
NAVNAVCO Pharmaceuticals Inc
$ 0,005
(-50,00%)
16,63k
SMAR.PSmartset Services Inc
$ 0,015
(-50,00%)
30k
ETUE2gold Inc
$ 0,005
(-50,00%)
101,7k
DDDMetavista3D Inc
$ 2,30
(-49,45%)
701,59k
MXL.HMX Gold Corp
$ 0,04
(-46,67%)
1,5k
NDANeptune Digital Assets Corp
$ 2,20
(30,18%)
5,15M
BRCBlackrock Silver Corp
$ 0,355
(-11,25%)
3,79M
TDGTDG Gold Corp
$ 0,45
(-1,10%)
3,19M
GPUSAlset AI Ventures Inc
$ 0,14
(-12,50%)
2,79M
PNGKraken Robotics Inc
$ 2,87
(0,35%)
2,69M
Aucune Discussion Trouvée
Ajouter une Discussion